Exelixis' Cabometyx, Roche's Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer PatientsBenzinga • 05/25/21
Pivotal Phase III data at ASCO show Roche's Tecentriq helps certain people with early lung cancer live significantly longer without their disease returningGlobeNewsWire • 05/20/21
Pivotal Phase III Data at ASCO Show Genentech's Tecentriq Helps Certain People With Early Lung Cancer Live Significantly Longer Without Their Disease ReturningBusiness Wire • 05/19/21
Analog Devices, Inc. (ADI) CEO Vince Roche on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/19/21
Roche receives FDA authorisation for testing of asymptomatic people with the cobas SARS-CoV-2 Test to help control the spread of COVID-19PRNewsWire • 05/18/21
Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancerGlobeNewsWire • 05/11/21
Genentech to Present Data From One of the Most Comprehensive Oncology Portfolios at the 2021 ASCO Annual Meeting Showcasing Advancements for People Living With CancerBusiness Wire • 05/11/21
Roche's Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancerGlobeNewsWire • 05/05/21
The Hanover Insurance Group, Inc. (THG) CEO Jack Roche on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/30/21
Oncologic Drugs Adcomm Backs Merck's Keytruda, Roche's Tecentriq Accelerated Approvals In Bladder CancerBenzinga • 04/29/21
FDA Advisory Committee Votes in Favor of Maintaining Accelerated Approval of Genentech's Tecentriq for Previously Untreated Metastatic Bladder CancerBusiness Wire • 04/28/21
US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche's Tecentriq for previously untreated metastatic bladder cancerGlobeNewsWire • 04/28/21
FDA Oncology Adcomm Votes To Keep Conditional Approval For Roche's Tecentriq In Place For NowBenzinga • 04/28/21
Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of peopleGlobeNewsWire • 04/28/21
FDA Advisory Committee Votes in Favor of Maintaining Accelerated Approval of Genentech's Tecentriq for PD-L1-Positive, Metastatic Triple-Negative Breast CancerBusiness Wire • 04/27/21
US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche's Tecentriq for PD-L1-positive, metastatic triple-negative breast cancerGlobeNewsWire • 04/27/21
FDA to discuss whether immuno-oncology drugs with 'accelerated' approval should remain on the marketMarket Watch • 04/26/21
Roche, AbbVie, Bristol-Myers Are Latest To Win European Medicines Agency's CHMP Positive OpinionBenzinga • 04/23/21
CHMP recommends EU approval of Roche's ENSPRYNG (satralizumab) for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD)GlobeNewsWire • 04/23/21
Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapyGlobeNewsWire • 04/23/21